Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

Though the original Resident Evil movies starring Milla Jovovich certainly found an audience, for many fans of the long-running survival horror video game series, we still haven't had a really great ...

President Trump on Wednesday claimed there was “nothing left” to bomb in Iran and that the war would end soon, the latest of what has often been conflicting messaging on the timeline of the conflict.

WASHINGTON, March 11 (Reuters) - U.S. President Donald Trump told Axios on Wednesday that there's "practically nothing left" to target in Iran ⁠and that the war there will end "soon." "Little this and ...

Abstract: Generating high-performance tensor programs on resource-constrained devices is challenging for current Deep Learning (DL) compilers that use learning-based cost models to predict the ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Forbes contributors publish independent expert analyses and insights. Rachel Wells is a writer who covers leadership, AI, and upskilling. And no, in case you were wondering, python is not a snake in ...

Amid a push toward AI agents, with both Anthropic and OpenAI shipping multi-agent tools this week, Anthropic is more than ready to show off some of its more daring AI coding experiments. But as usual ...

My little theory is that the concept of “imprinting” in psychology can just as easily be applied to programming: Much as a baby goose decides that the first moving life-form it encounters is its ...

In some ways, Java was the key language for machine learning and AI before Python stole its crown. Important pieces of the data science ecosystem, like Apache Spark, started out in the Java universe.

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...